Chronic Lymphocytic Leukemia

The FDA has updated the label for obinutuzumab plus chlorambucil to include data from stage 2 of the phase III CLL11 study, which detailed an unprecedented improvement in progression-free survival compared with rituximab plus chlorambucil as a frontline treatment for patients with chronic lymphocytic leukemia.

Idelalisib monotherapy shows activity in treatment-naïve patients ≥65 years with CLL or SLL, with nearly 90% of patients enrolled in a phase II study demonstrating a partial response.

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the efficacy and safety of the combination of idelalisib and rituximab for older patients with chronic lymphocytic leukemia.

Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses exciting new therapies for lymphomas and chronic lymphocytic leukemia (CLL).

Juno Therapeutics, Inc, has filed a registration statement for an initial public offering of its common stock, as its early stage therapies continue to advance in clinical trials.

When Marcela V. Maus, MD, PhD, thinks of the challenge of bringing chimeric antigen receptor (CAR) therapies to market in the battle against cancer, she is reminded of the auto industry's first days.

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses lymphocytosis following treatment with a B-cell receptor inhibitor.

As the targeted therapy era in chronic lymphocytic leukemia (CLL) continues to unfold, two next-generation agents are generating responses with improved safety profiles as single agents and in combination regimens

Ibrutinib has been approved by the European Commission for the treatment of adult patients with relapsed or refractory MCL and adult patients with CLL.

The treatment landscape for patients with chronic lymphocytic leukemia (CLL) is rapidly changing, with the emergence of four new therapeutic options for this malignancy in recent months.

Infinity Pharmaceuticals has entered into two separate agreements with Roche and AbbVie to develop and commercialize duvelisib (IPI-145), an oral inhibitor of PI3K-delta and PI3K-gamma, for the treatment of patients with hematologic malignancies.

TG Therapeutics has reached an agreement with the FDA regarding a Special Protocol Assessment for a phase III clinical trial exploring ublituximab in combination with ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the phase III RESONATE trial.